![]() |
市場調査レポート
商品コード
1541658
血液浄化装置市場レポート:製品タイプ、適応症、エンドユーザー、地域別、2024~2032年Blood Purification Equipment Market Report by Product Type (Portable, Stationary), Indication (Sepsis, Renal Diseases, and Others), End User (Hospitals and Clinics, Dialysis Centers, and Others), and Region 2024-2032 |
||||||
カスタマイズ可能
|
血液浄化装置市場レポート:製品タイプ、適応症、エンドユーザー、地域別、2024~2032年 |
出版日: 2024年08月10日
発行: IMARC
ページ情報: 英文 137 Pages
納期: 2~3営業日
|
世界の血液浄化装置市場規模は2023年に209億米ドルに達しました。今後、IMARC Groupは、2024~2032年にかけての成長率(CAGR)は6%を示し、2032年までに359億米ドルに達すると予測しています。
血液浄化装置とは、患者の血液を抽出・浄化するための医療機器を指します。不純物を除去するために血液を抜き取り、浄化された血液をポンプで体内に戻します。一般的に使用される機器には、血液透析、血液濾過、持続的腎代替療法(CRRT)、血液灌流、血漿交換装置などがあります。これらは一般的に、臓器不全や腎不全、免疫代謝異常の治療やプラズマフェレーシス処置に利用され、病院、クリニック、外来手術センターなどで広く使用されています。
世界中で代謝、免疫、腎臓関連疾患の有病率が増加していることが、市場の成長を促進する主要要因の1つです。さらに、糖尿病、高血圧、腎不全などの病気にかかりやすい高齢者人口の増加が、市場の成長を後押ししています。コロナウイルス病(COVID-19)が蔓延し続ける中、医療センター全体で血液浄化装置への要求が大幅に増加しています。これらの装置は、病原体、サイトカイン、その他の炎症性メディエーターを血液から濾過し、細胞の免疫反応を改善します。さらに、バイオフィードバック・ループや個別化された透析処方機能を備えた装置の開発など、さまざまな製品革新が他の成長促進要因として作用しています。これらの新機軸は、透析内低血圧の予防、透析中のモニタリングの改善、電子カルテ(EMR)の維持に役立っています。これに伴い、製品メーカー各社は、家庭でのケアに使用できるポータブルで経済的な血液浄化装置の開発も進めています。その他にも、大衆の健康意識の高まりや、特に新興経済諸国における医療インフラの改善などが、市場の成長を後押しすると予想されます。
The global blood purification equipment market size reached US$ 20.9 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 35.9 Billion by 2032, exhibiting a growth rate (CAGR) of 6% during 2024-2032.
Blood purification equipment refers to the medical devices used for extracting and purifying the patient's blood. The equipment withdraws the blood to remove impurities and pumps the purified blood back into the body. Some of the commonly used equipment include hemodialysis, blood filtration, continuous renal replacement therapy (CRRT), hemoperfusion and plasma exchange devices. They are commonly utilized for the treatment of organ or renal failures and immune-metabolic disorders and for plasmapheresis procedures and are widely used across hospitals, clinics and ambulatory surgical centers.
The increasing prevalence of metabolic, immune and kidney-related disorders across the globe is one of the key factors driving the growth of the market. Furthermore, rising geriatric population, which is more susceptible to ailments, such as diabetes, hypertension and renal failure, is providing a thrust to the market growth. As the coronavirus disease (COVID-19) continues to spread, there is a significant increase in the requirement for blood purification devices across healthcare centers. These devices filter the pathogens, cytokines and other inflammatory mediators from the blood to improve the cell's immune response. Additionally, various product innovations, such as the development of equipment with biofeedback loops and personalized dialysis prescription capabilities, are acting as other growth-inducing factors. These novel variants aid in preventing intradialytic hypotension, improving monitoring during dialysis and maintaining electronic medical records (EMRs). In line with this, product manufacturers are also developing portable and economical blood purification equipment, which can be used for at-home care settings. Other factors, including rising health consciousness among the masses, along with improvements in the medical infrastructure, especially in the developing economies, are anticipated to drive the market toward growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the global blood purification equipment market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product type, indication and end user.
Portable
Stationary
Sepsis
Renal Diseases
Others
Hospitals and Clinics
Dialysis Centers
Others
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Aethlon Medical Inc., Asahi Kasei Corporation, B. Braun Melsungen AG, Baxter International Inc., Cerus Corporation, CytoSorbents Corporation, Fresenius SE & Co. KGaA, Healthwell Medical Tech. Co. Ltd., Jafron Biomedical Co. Ltd., Kaneka Corporation, Medtronic plc, Nikkiso Co ltd., and Spectral Medical Inc.